Ozmosi | Oxaliplatin Drug Profile

Product Description

Oxaliplatin is a type of chemotherapy drug. It is also called Eloxatin. It's a treatment for bowel cancer and some other types of cancer. You usually have oxaliplatin in combination with other chemotherapy drugs. It depends on the type of cancer you have as to which drugs you have it with. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/oxaliplatin-eloxatin)

Mechanisms of Action: DNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oxaliplatin

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 92

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Epilepsy|Muscle Spasticity|Oncology Solid Tumor Unspecified

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT05476796	LOGICAN	P2	Recruiting	Adenocarcinoma\|Esophageal Cancer\|Gastrointestinal Cancer	2026-01-01	41%	2023-10-18	Primary Endpoints\|Start Date\|Treatments
NCT06247956	SHR-8068-201-GC	P2	Active, not recruiting	Adenocarcinoma\|Esophageal Cancer\|Gastrointestinal Cancer\|Squamous Cell Carcinoma	2025-12-30	2%	2025-09-04	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Treatments\|Trial Status
2025-520471-29-00	FCO-FOX-2024-01	P3	Not yet recruiting	Colorectal Cancer\|Adenocarcinoma\|Colic	2030-12-31
NCT06571461	HE072-006	P3	Not yet recruiting	Pancreatic Cancer	2028-01-01	17%	2024-11-27	Primary Endpoints\|Treatments
NCT06929624	SHR-A1912-301	P3	Recruiting	Diffuse Large B-Cell Lymphoma	2027-03-01	71%	2025-05-14	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT05144854	ONO-4538-113	P3	Active, not recruiting	Gastrointestinal Cancer	2026-05-01	86%	2024-09-06	Primary Completion Date\|Primary Endpoints\|Treatments
NCT05253651	MOUNTAINEER-03	P3	Recruiting	Colorectal Cancer	2026-04-03	42%	2025-02-22
NCT04469556	PASS-01	P2	Completed	Pancreatic Cancer\|Adenocarcinoma\|Pancreatic Ductal Carcinoma	2025-03-05		2026-02-21	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
CTR20200664	CTR20200664	P1	Completed	Oncology Solid Tumor Unspecified	2023-06-08		2025-04-29	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT05494060	EXPLORING	P2	Recruiting	Esophageal Diseases\|Adenocarcinoma\|Gastrointestinal Cancer\|Digestive System Cancer\|Intestinal Diseases\|Esophageal Cancer\|Stomach Diseases	2024-12-01	41%	2023-11-08	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT04430738	SGNTUC-024	P2	Active, not recruiting	Gastrointestinal Cancer\|Esophageal Cancer\|Cholangiocarcinoma\|Colorectal Cancer\|Bladder Cancer\|Adenocarcinoma	2024-07-31	12%	2025-09-10	Primary Endpoints
2017-000927-29	CRC-PIPAC	P2	Active, not recruiting	Colorectal Cancer\|Peritoneal Cancer	2020-01-31		2022-03-13	Treatments
ACTRN12619001723178p	2006-7041-83/hah	P1	Not yet recruiting	Muscle Spasticity\|Epilepsy	2020-02-24
NCT06258525	IIT2022-11-Gangi-SAMe	P2	Not yet recruiting	Hepatic Veno-Occlusive Disease\|Chemical and Drug Induced Liver Injury\|Colorectal Cancer\|Liver Cancer	2028-04-01	2%	2025-11-05
NCT07146646	CASE2225	P2	Recruiting	Gallbladder Cancer\|Cholangiocarcinoma\|Biliary Tract Cancer	2027-02-01		2025-11-13	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT06806033	GO45434	P2	Recruiting	Lymphoma, Non-Hodgkin\|Lymphoma, B-Cell	2027-01-31	12%	2025-12-24	Primary Endpoints\|Start Date\|Study Completion Date\|Treatments
NCT06205485	NEO-RT	P3	Recruiting	Colorectal Cancer	2030-01-30		2024-08-14	Primary Endpoints\|Start Date
NCT06624085	GO44900	P1	Recruiting	Diffuse Large B-Cell Lymphoma	2030-03-31	50%	2025-06-05	Primary Completion Date\|Primary Endpoints\|Treatments
2022-501181-22-01	STEREOPAC-001	P2	Recruiting	Pancreatic Cancer\|Adenocarcinoma	2032-10-01		2025-05-02	Treatments
2023-509814-12-00	2023-509814-12-00	P2	Recruiting	Colorectal Cancer	2031-03-31		2025-05-02
2020-003134-20	MEND-IT	P2	Active, not recruiting	Colorectal Cancer	2030-05-17		2022-03-13	Treatments
NCT07281768	J25118	P2	Not yet recruiting	Adenocarcinoma\|Colorectal Cancer	2030-03-01	12%	2025-12-16	Primary Endpoints\|Treatments
2024-516791-15-00	GO45434	P2	Recruiting	Diffuse Large B-Cell Lymphoma	2029-04-30		2025-05-02	Treatments
2025-523261-25-00	2025-523261-25-00	P2	Not yet recruiting	Colorectal Cancer	2029-03-01
NCT07437287	CROCOBIL	P3	Not yet recruiting	Biliary Tract Cancer	2030-04-01	30%	2026-02-28	Primary Endpoints\|Treatments

Recent News Events

Date	Type	Title
02/12/2026	News Article	Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
02/02/2026	News Article	Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
01/20/2026	News Article	Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
01/16/2026	News Article	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Oxaliplatin

Alternative Names: oxaliplatin, act-078, eloxatin, xa-03, xa 03, xa03, OXALIPLATINO Clinical Status: Inactive Latest Update: 2026-03-02 Latest Update Note: Clinical Trial Update